HASBROUCK HEIGHTS, N.J., Nov. 23, 2009 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today the release of positive new clinical trial data from responder analysis of the Company’s pooled multi-center U.S. Phase 2 studies of NX-1207, indicating durable early responder benefits from Nymox’s innovative drug treatment for benign prostatic hyperplasia (BPH). The study concerned patients who reported a 6 point or better improvement in BPH Symptom Score improvement within a month of treatment (early responders). At follow-up (14 months on average post-treatment), proportionally there were over 4.3 times as many NX-1207 early responders who had maintained a 6 point or better improvement in symptom score and who did not require further BPH treatment of any kind as compared to placebo controls.
